TrialBritish journal of cancer2023

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.

Yasutoshi Kuboki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.